| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C12H16N2O11V |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
VO-Ohpic trihydrate is a highly potent inhibitor of PTEN, with an IC50 of 46±10 nM. It is supplied as a light green to green solid (C12H16N2O11V, MW 415.20) at 95% purity.
Physical & Chemical Properties
| CAS Number | 476310-60-8 |
|---|---|
| Molecular Formula | C12H16N2O11V |
| Molecular Weight | 415.20 g/mol |
| Purity | 95% |
| Appearance | Solid |
| Color | Light green to green |
| SMILES | O[V+2]([N]1=CC=CC(O)=C1C2=O)([O-]2)([O-]C3=CC=CN=C3C4=O)([O-]4)=O.[H+].[3H2O] |
| Signaling Pathway | PI3K/Akt/mTOR; Autophagy |
| Solubility | In Vitro: DMSO: ≥ 50 mg/mL (120.42 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O: < 0.1 mg/mL (insoluble) * "≥" means soluble, but saturation unknown. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years. In solvent: -80°C, 6 months; -20°C, 1 month. |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Biological Activity
IC50 & Target
IC50: 46±10 nM (PTEN)[1]
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
[1]. Mak LH, et al. Characterisation of the PTEN inhibitor VO-OHpic. J Chem Biol. 2010 Oct;3(4):157-63.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | ≥ 50 mg/mL (120.42 mM) | use freshly opened DMSO (absorbed moisture lowers solubility) |
| H2O | < 0.1 mg/mL | insoluble |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 2.5 mg/mL (6.02 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 2.5 mg/mL (6.02 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 2.5 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (25.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Data provided by the manufacturer.
In Vitro
VO-OHpic, which carries two OHpic ligands and an oxo ligand, is a sterically demanding molecule, so substrate binding would be expected to affect later inhibitor binding through steric hindrance. VO-OHpic significantly inhibits PTEN activity at low nanomolar concentrations (IC50, 46±10 nM), consistent with the potency determined earlier (IC50, 35±2 nM) in a PIP3-based assay. The Kic and Kiu inhibition constants are measured as 27±6 and 45±11 nM, respectively[1]. Encouragingly, VO-OHpic is a specific and potent PTEN inhibitor, and the most potent inhibitor (IC50=35 nM) of PTEN lipid phosphatase activity[2].
In Vivo
Mice receive an intra-peritoneal injection of VO-OHpic (10 μg/kg) 30 min before ischemia to inhibit PTEN, then undergo 30 min of ischemia and 120 min of reperfusion. Myocardial infarct size is measured by triphenyltetrazolium chloride (TTC) at the end of the experiment. VO-treated mice show significantly smaller myocardial infarct size (25±6 vs. 56±5 %, n=7, P<0.01). The area at risk does not differ between these groups (46±3 vs. 57±3 %, n=7, P>0.05)[3].
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Kinase Assay[1]
Dissolve VO-OHpic in DMSO (100 μM) and dilute further to the required concentration with 1% DMSO. For inhibition studies, preincubate PTEN with VO-OHpic at RT for 10 min, then add substrate to initialize the reaction. Determine background absorbance (malachite green assay) and fluorescence (OMFP assay) with VO-OHpic in assay buffer and correct for them in the data analysis[1].
Animal Administration[3]
Mice[3] Use male C57BL6 mice. Anesthetize the mice with pentobarbital (70 mg/kg). Occlude the left coronary artery about 1-2 mm below the left auricle, and reperfuse by loosening the ligature. Administer the PTEN inhibitor VO-OHpic by intra-peritoneal injection at a dosage of 10 μg/kg once, 30 min before ischemia. Use saline as control. At the end of the experiment, euthanize the animals by transecting the aorta and remove the heart for infarct size determination.
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
A small-molecule cocktail promotes mammalian cardiomyocyte proliferation and heart regeneration. Cell Stem Cell 2022 Apr 7;29(4):545-558.e13. PMID: 35395187
NUMB maintains bone mass by promoting degradation of PTEN and GLI1 via ubiquitination in osteoblasts. Bone Res 2018 Nov 10:6:32.
Salidroside sensitizes Triple-negative breast cancer to ferroptosis by SCD1-mediated lipogenesis and NCOA4-mediated ferritinophagy. J Adv Res 2025 Aug:74:589-607. PMID: 39353532
ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis. Redox Biol 2024 Jul:73:103200. PMID: 38781729
Resveratrol as a new inhibitor of immunoproteasome prevents PTEN degradation and attenuates cardiac hypertrophy after pressure overload. Redox Biol 2019 Jan:20:390-401.
An orally-administered nanotherapeutics with gold nanospheres supplying for rheumatoid arthritis therapy by re-shaping gut microbial tryptophan metabolism. J Nanobiotechnology 2025 May 25;23(1):376. PMID: 40414887
Spontaneous evolution of human skin fibroblasts into wound-healing keratinocyte-like cells. Theranostics 2019 Jul 9;9(18):5200-5213.
Embryonic Stem Cells Modulate the Cancer-Permissive Microenvironment of Human Uveal Melanoma. Theranostics 2019 Jul 9;9(16):4764-4778.
ZC3H15 regulates the ubiquitination of PTEN via recruitment of TRIM56 and promotes malignant progression of non-small cell lung cancer. Cell Death Dis 2026 Jan 9;17(1):17. PMID: 41513632
Activation of AKT via a dual mechanism enhances the susceptibility of melanoma cells to glucose deprivation. Cell Death Dis 2025 Aug 7;16(1):595. PMID: 40774947
